WHO ICTRP trial
A phase II trial of PAD (Bortezomib, Doxorubicin and Dexamethasone) induction…
ACTRN12609000296235 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting
Key facts
| Trial ID | ACTRN12609000296235 |
|---|---|
| Public title | A phase II trial of PAD (Bortezomib, Doxorubicin and Dexamethasone) induction therapy in transplant-eligible patients with untreated multiple myeloma (MM), stratified for markers of bortezomib resistance. |
| Scientific title | A phase II trial of PAD (Bortezomib, Doxorubicin and Dexamethasone) induction therapy in transplant-eligible patients with untreated multiple myeloma (MM), stratified for markers of bortezomib resistance, comparing overall response rate to PAD (Bortezomib, Doxorubicin and Dexamethasone). |
| Primary sponsor | Janssen-Cilag Pty Ltd |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 2 |
| Countries | Australia |
| Conditions | Multiple Myeloma; Multiple Myeloma;Cancer - Myeloma |
| Interventions | Four 21-day cycles of PAD: a combination of bortezomib i.v. (intravenous) 1.3mg/m2 (Days 1,4, 8 and 11), doxorubicin i.v. 20mg/m2 (days 1 and 4) and dexamethasone p.o. (by mouth) (days 1, 2, 4, 5, 8, 9, 11 and 12). Days 13 to 21 will be… |
| Registration date | May 18, 2009 |
| Target size | 105 |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: